Breaking Finance News

Zacks Investment Research disclosed Vascular Biogenics Ltd (NASDAQ:VBLT), bumping up its stock price target to $4.50 earlier today

Yesterday Vascular Biogenics Ltd (NASDAQ:VBLT) traded 4.20% higher at $4.10. The company’s 50-day average is $4.18 and its two hundred day moving average is $3.84. The last stock price close is up 22.69% relative to the two hundred day average, compared to the S&P 500 which has decreased -0.01% over the date range. Trading volume was was down over the average, with 187,250 shares of VBLT changing hands under the typical 377,145 shares..

Vascular Biogenics Ltd (NASDAQ:VBLT) had its estimated target price upped to $5 by Zacks Investment Research in a report released 8/18/2016. The latest target price suggests a potential upside of 0.10% from the bussiness’ previous stock close price.

On Tuesday June 28 2016, H.C. Wainwright reported on Vascular Biogenics Ltd(NASDAQ:VBLT) bumped the target price from $0.00 to $11.00 that indicated a possible upside of 1.56%.

Performance Chart:

Vascular Biogenics Ltd (NASDAQ:VBLT)

A total of 5 analysts have released a research note on the company. Zero rate the stock a strong buy, four analysts rate the company a buy, 0 firms rate the stock a hold, 0 rate the stock to underperform, and lastly 0 brokeragesrate the stock as sell with a 12-month target of $15.00

With a market cap of $0.0, Vascular Biogenics Ltd has a P/E of 0 with a one-year low of $2.76 and a one-year high of $12.25.

Brief Synopsis About Vascular Biogenics Ltd (NASDAQ:VBLT)

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, and is a Phase II-ready molecule.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *